ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the hottest large-cap stocks of 2025. On December 16, Piper Sandler raised the firm’s price target on Abivax to $142 from$112, while maintaining an Overweight rating on the shares. On the same day, Citizens raised the firm’s price target on ABIVAX Société Anonyme (NASDAQ:ABVX) to $131 from$114, while keeping an Outperform rating on the shares. The firm highlighted that Abivax’s Q3 2025 results and operational milestones, specifically noting that the Phase 3 ...